Alexandra S Troyan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5344071/publications.pdf

Version: 2024-02-01

10	177	7	9
papers	citations	h-index	g-index
10	10	10	327 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Poststroke Depression Biomarkers: A Narrative Review. Frontiers in Neurology, 2018, 9, 577.	2.4	61
2	Insulin-like growth factor-1: a possible marker for emotional and cognitive disturbances, and treatment effectiveness in major depressive disorder. Annals of General Psychiatry, 2017, 16, 38.	2.7	32
3	Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram. Journal of Affective Disorders, 2019, 250, 114-122.	4.1	27
4	Plasma Brain-Derived Neurotrophic Factor as a Biomarker for the Main Types of Mild Neurocognitive Disorders and Treatment Efficacy: A Preliminary Study. Disease Markers, 2016, 2016, 1-7.	1.3	22
5	The Diagnostic Value of the Combination of Serum Brain-Derived Neurotrophic Factor and Insulin-Like Growth Factor-1 for Major Depressive Disorder Diagnosis and Treatment Efficacy. Frontiers in Psychiatry, 2020, 11, 800.	2.6	11
6	Serum insulin-like growth factor-1 as a potential marker for MDD diagnosis, its clinical characteristics, and treatment efficacy validation: data from an open-label vortioxetine study. BMC Psychiatry, 2020, 20, 208.	2.6	10
7	Major depressive disorder and accelerated aging from a peripheral IGF-1 overexpression perspective. Medical Hypotheses, 2020, 138, 109610.	1.5	7
8	Neuropsychiatric Symptoms in Patients with the Main Etiological Types of Mild Neurocognitive Disorders: A Hospital-Based Case–Control Study. Frontiers in Psychiatry, 2017, 8, 75.	2.6	6
9	Specific Cognitive–Psychopathological Phenotypes in Patients With Early Stages of Subcortical Vascular Neurocognitive Disorders: A Hospital-Based Case–Control Study. Journal of Geriatric Psychiatry and Neurology, 2018, 31, 256-264.	2.3	1
10	P300 parameters as markers for early stages of subcortical vascular neurocognitive disorder and treatment efficacy. European Neuropsychopharmacology, 2017, 27, S1037-S1038.	0.7	0